Pure ground-glass nodules are faint, cloud-like lesions that appear on CT scans without any solid, opaque core. They have become increasingly common discoveries as low-dose CT lung screening spreads worldwide, and they represent a spectrum of disease ranging from atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS)—considered non-invasive, indolent lesions—through minimally invasive adenocarcinoma (MIA) to fully invasive adenocarcinoma (IAC). The clinical dilemma is acute. Non-invasive lesions may never harm a patient and can often be safely watched with serial imaging, while invasive ones typically require surgical resection, ranging from wedge resection to lobectomy. Yet on conventional CT images, these lesions can look nearly identical. Resecting every nodule would burden patients with complications, costs and anxiety; watching every nodule could delay treatment for those that are quietly becoming invasive.

The Tianjin team, led by Jun Lv and corresponding author Hong Zhang, attacked the problem on two fronts: better images and smarter analysis of those images. On the imaging side, the researchers used a technique called large matrix target reconstruction. Standard chest CT images are reconstructed at a 512 × 512 pixel matrix over a field of view of roughly 350 millimetres, yielding a pixel size of about 0.68 millimetres. For nodules smaller than 15 millimetres, this coarse resolution produces partial volume effects—where each pixel averages tissue signals together—that blur the subtle internal architecture radiologists rely on. Instead, the team reconstructed targeted images at a 1,024 × 1,024 matrix over a reduced 70-millimetre field of view centred on the nodule, cutting pixel size to approximately 0.068 millimetres. That is roughly a tenfold improvement in spatial resolution, allowing finer delineation of tumour margins, minute solid components and microvascular changes that conventional reconstructions can miss.

On the analytical side, the researchers embraced radiomics, the practice of extracting hundreds of quantitative features from medical images—features invisible to the human eye but potentially reflective of underlying tumour biology. From each lesion, the team’s pipeline, built on the open-source PyRadiomics library, extracted a remarkable 1,834 quantitative features. These fell into three broad categories: shape descriptors capturing the three-dimensional geometry of the nodule; first-order statistics describing the distribution of CT intensity values within it; and texture features quantifying spatial heterogeneity, computed from matrices such as the grey-level co-occurrence matrix, grey-level run length matrix, grey-level size zone matrix, grey-level dependence matrix and neighbouring grey-tone difference matrix. Because so many features invite statistical overfitting, the team applied least absolute shrinkage and selection operator (LASSO) regression with ten-fold cross-validation, which whittled the feature set down to 11 non-zero features carrying the most predictive information.

The study population consisted of 297 patients—86 men and 211 women, aged 19 to 76 with a mean age of 56—all of whom underwent surgical resection at Tianjin Chest Hospital between March 2021 and June 2024, providing the pathological “ground truth” against which the models were tested. After exclusions for benign lesions, prior malignancies, solid or part-solid nodules, lesions larger than 1.5 centimetres and poor image quality, the final cohort comprised 93 patients with non-invasive lesions (AAH or AIS) and 204 with invasive ones (MIA or IAC). The cohort was split 7:3 into a training set of 207 cases and a validation set of 90, using stratified random sampling to preserve the balance of pathological classes. Every pathological diagnosis was rendered by two board-certified thoracic pathologists with more than a decade of experience, blinded to imaging, working to the 2021 World Health Organization classification.

The clinical and imaging data alone told a compelling story. Invasive lesions were larger, averaging 17.2 millimetres in maximum diameter versus 14.5 millimetres for non-invasive ones, denser on CT—mean densities of −642 versus −671.5 Hounsfield units—and carried a much higher solid component ratio, 56.2 percent versus 35.3 percent. Invasive nodules were also more likely to be irregular in shape, lobulated, spiculated, associated with pleural indentation, microvascular changes and cavitation, and their owners were more likely to be older, male and to have a smoking history. Multivariate logistic regression distilled these down to three independent predictors: maximum lesion diameter, median CT value and the solid component ratio. Each millimetre of added diameter raised the odds of invasiveness by roughly 77.6 percent, and each Hounsfield unit of increased median density raised them by 1.5 percent.

The models themselves, however, delivered the headline result. Built in Python with logistic regression and five-fold cross-validation, the radiomics-only model achieved an area under the receiver operating characteristic curve (AUC) of 0.861 (95 percent confidence interval 0.811–0.912) in the training set and 0.790 (95 percent CI 0.687–0.892) in the validation set, with sensitivity of 78.7 percent and specificity of 65.5 percent in validation. The combined model, integrating clinical features with radiomics, reached an AUC of 0.861 (95 percent CI 0.809–0.913) in training and 0.810 (95 percent CI 0.709–0.912) in validation, with validation sensitivity climbing to 90.2 percent. In the validation cohort, the combined model significantly outperformed both the radiomics-only and clinical-only models, while decision curve analysis showed the combined model delivered the greatest net clinical benefit whenever the decision threshold probability exceeded 40 percent—the very zone where surgeons wrestle with the operate-versus-observe choice. Calibration curves and the Hosmer–Lemeshow test confirmed the model’s predictions tracked actual outcomes well in both cohorts.

To make the tool usable at the bedside, the team packaged their findings into a nomogram—a graphical calculator that assigns points for a patient’s clinical profile and radiomics signature, sums them, and converts the total into a probability of invasiveness. The authors argue its greatest value lies in reclassifying intermediate-risk nodules, the ambiguous middle ground where management decisions are hardest. By sharpening the risk estimate in these cases, the tool could reduce both unnecessary operations on indolent lesions and delayed interventions on minimally invasive cancers, where early surgery offers the best chance of cure.

The researchers were candid about the technical subtleties in their data. Correlation analysis showed that some first-order radiomics features, such as the median and mean intensity statistics, correlated strongly with the conventional CT density measurements (correlation coefficients of 0.81 to 0.89), raising the question of redundancy. Yet higher-order texture features—such as dependence entropy and grey-level non-uniformity—showed weak correlations with clinical HU variables and captured spatial patterns of tumour heterogeneity that simple density averages cannot. Variance inflation factor analysis confirmed acceptable multicollinearity in the combined model, and the modest but consistent improvement in validation performance suggested the radiomics features contributed genuinely complementary information, reflecting tumour microarchitecture rather than mere intensity.

The study’s limitations are real and the authors acknowledge them squarely. It was retrospective and single-centre, relying on a single CT scanner—the Philips Brilliance iCT 256—and a specific reconstruction protocol, which may limit generalisability. Validation was internal rather than external, and the three-dimensional tumour segmentations were performed manually by experienced radiologists, a laborious process that can introduce variability, though inter-observer Dice similarity coefficients of 0.85 to 0.92 indicated excellent agreement. The team also lacked a direct comparison arm using conventional 512-matrix reconstruction, so the precise incremental benefit of the high-resolution technique remains to be quantified in a controlled design. The authors call for prospective, multicentre validation across diverse scanners and populations, noting also that subsolid nodule behaviour differs between Asian and Western populations, with higher pGGN prevalence and overdiagnosis concerns in East Asia.

Even with those caveats, the work represents a meaningful step toward precision management of a lesion type that millions of screening participants now carry. The convergence of ultra-high-resolution targeted reconstruction—essentially giving the radiologist a magnifying glass with a thousand-fold finer grid—and statistical learning over thousands of quantitative image features offers a non-invasive window into tumour biology that previously required a scalpel to obtain. If external validation confirms these results, the humble chest CT, paired with algorithms running quietly in the background, could become the difference between watchful waiting and the operating room for patients with tiny ground-glass nodules—and could do so before a single cell has breached a basement membrane.

In an initial study, the test distinguished people with stage 2–4 lung cancer from healthy individuals with a sensitivity of 93.1% and a specificity of 90.3%. Sensitivity measures how accurately a test identifies people who have a disease, while specificity reflects how reliably it rules out disease in people who do not have it. Although the results are preliminary and will require validation in much larger populations, the performance suggests that the technology could eventually complement medical imaging in the diagnosis and monitoring of lung cancer.

The approach focuses on cell-free DNA, small fragments released into the bloodstream when cells die. Blood contains DNA from many tissues, but tumor-derived fragments can carry molecular patterns that differ from those found in healthy cells. Rather than reading the complete genetic sequence of each fragment, the researchers analyze chemical characteristics associated with specific genomic regions. These patterns can reflect changes in the way cancer cells package and regulate their DNA, creating a molecular signature that is detectable even when the fragments themselves are present in small amounts.

To measure this signature, the team first extracts cell-free DNA from a blood sample and attaches a light-emitting label to it. The labeled material is then exposed to a specially designed DNA chip containing probes corresponding to selected genomic regions. If fragments in the sample interact with particular probes, the chip produces a characteristic optical pattern. A scanner records the pattern, and analytical software compares it with profiles associated with cancer or healthy tissue. The process converts a complex molecular signal into a visual readout that can be interpreted without sequencing the entire genome.

The researchers initially identified a panel of 170 genomic regions that together formed a diagnostic signature. Their study included 103 participants: 51 people with lung cancer and 52 healthy control subjects. After training a model using part of the data, the team evaluated the signature in a separate validation group under blinded conditions, meaning the analysis was performed without revealing the participants’ clinical status. The strong results in this testing phase indicate that the signature was not simply recognizing obvious differences in the original training samples.

The chip also showed promise in distinguishing between two major forms of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. These cancers arise from different types of cells and can respond differently to treatment. Their distinct DNA-associated patterns suggest that the technology may eventually provide more than a simple positive-or-negative result. With further research, the same platform could help characterize tumor subtypes and support more individualized decisions about diagnosis and therapy.

The researchers also explored whether the test could track how patients respond to treatment. In patients whose tumors responded according to medical imaging, the blood-based chemical fingerprint shifted toward the pattern observed in healthy individuals. Patients who did not respond showed no comparable change. This finding raises the possibility that a blood test could provide an additional, less invasive way to follow disease activity between scans. However, the monitoring analysis involved a limited number of patients and should be considered exploratory until confirmed in prospective, large-scale clinical studies.

The need for improved tools is substantial. Lung cancer remains the leading cause of cancer-related death worldwide, yet detecting it early can be difficult. Computed tomography scans can identify suspicious nodules, but many of these findings are ultimately benign. False-positive results may lead to repeated imaging, invasive biopsies, anxiety, and occasionally unnecessary surgery. Existing liquid biopsies can offer molecular information, but sequencing-based systems often require costly instruments, specialized personnel, and substantial computational resources.

According to the research team, the new test could be completed in approximately two to three days at an estimated cost of about $60 per sample. Those figures could make the platform attractive for laboratories that cannot support comprehensive sequencing workflows. Still, the test is not a replacement for CT imaging or pathological examination, and its reported accuracy does not yet establish how it would perform in routine screening, where many tested individuals would not have cancer. The next steps will include recruiting larger and more diverse patient groups, testing earlier-stage disease, and determining how the method performs alongside established clinical tools.

The Tel Aviv University study, conducted with collaborators from JaxBio Technologies, Bnai Zion Medical Center, and Sheba Medical Center, points toward a different model for liquid biopsy: instead of decoding every letter of tumor DNA, clinicians may be able to recognize cancer through a compact optical signature. If future studies confirm the findings, a simple DNA-chip assay could help reduce diagnostic delays, distinguish lung cancer subtypes, and provide a convenient way to monitor treatment response. For now, the technology remains an investigational advance, but its combination of speed, affordability, and sequencing-free molecular analysis makes it one of the more intriguing developments in the search for accessible cancer diagnostics.

Subject of Research: A sequencing-free blood test using cell-free DNA and a DNA chip to detect and characterize lung cancer.

Article Title: A Simple, Low-Cost Blood Test on a Chip Diagnoses Lung Cancer Without DNA Sequencing

Web References: https://doi.org/10.1038/s41698-026-01547-2; Study video

References: npj Precision Oncology, DOI: 10.1038/s41698-026-01547-2

Image Credits: Tel Aviv University

Keywords

Lung cancer, cancer diagnosis, liquid biopsy, cell-free DNA, DNA chip, DNA methylation, optical scanning, precision oncology, cancer biomarkers, treatment monitoring